This study aims to investigate the effect and mechanism of Vav3 on the multidrug resistance of gastric cancer. Fluorescence quantitative RT-PCR and western blot assay were used to detect Vav3 and drug resistance genes in gastric cancer tissues as well as gastric cell lines such as SGC7901, SGC7901/adriamycin (ADR) and GES-1. Besides, Vav3-specific small interfering RNA (Vav3-siRNA) was applied to inhibit Vav3 in SGC7901/ADR, and SRB assay was used to determine chemosensitivity. After that, drug resistance genes and proteins in MAPK and PI3K/AKT signaling pathway were detected after Vav3-siRNA transfection. The results showed that overexpressed Vav3 was found in gastric cancer tissues and SGC7901 and SGC7901/ADR cells. Activity of SGC7901/ADR cells transfected with Vav3-siRNA combined with 5-fluorouracil/oxaliplatin was much lower than that of control groups, and MDR1/P-gp, GST-π and Bcl-2, Bax genes were significantly downregulated in Vav3-siRNA transfection group. AKT, ERK and p38 total protein and their phosphorylation levels showed no significant change in Vav3-siRNA-transfected SGC7901/ADR cells, whereas the ratio of C-Jun phosphorylation levels to total C-Jun protein was significantly downregulated. The results suggested that Vav3 may play a role in drug resistance of gastric cancer by inhibiting drug resistance genes MDR1/P-gp, GST-π and Bcl-2 through regulating the JNK signaling pathway.
INTRODUCTION
Gastric cancer, the most common gastrointestinal malignancy in Asia, is currently the second leading cause of death from cancer in the world. Conventional methods in clinical treatment of gastric cancer involve surgery, radiotherapy, chemotherapy and biological therapy, among which surgery is still the most effective treatment. But because the early diagnostic rate of gastric cancer is 10%, adjuvant chemotherapy is available for those patients with advanced gastric cancer. 1, 2 However, the curative effect of chemotherapy is often affected by tumor heterogeneity and multidrug resistance (MDR). MDR is defined as crossresistance to drugs with other type of structure and mechanism of action due to drug resistance of tumor cells induced by the chemotherapeutic agents, which has a complex molecular mechanism. [3] [4] [5] MDR may directly lead to the failure of chemotherapy. Therefore, it is of great significance to solve the problem of MDR in gastric cancer.
Vav3 is one of guanine nucleotide exchange factors, and also activators of small GTP kinases in Rho family, which activates RhoA, Racl, Cdc42 and so on. Many studies have shown that Vav3 plays an important role in tumor development and metastasis. 6 It has been reported that Vav3 was overexpressed in bladder cancer, lymphoma and breast cancer. [7] [8] [9] Obviously, Vav3 may be used as a target in cancer treatment and biomarkers for tumor development, invasion and metastasis, and prognosis. Our previous study has also shown that Vav3 expression was upregulated in gastric cancer cells, and the growth of gastric cancer cells is inhibited as Vav3 expression is inhibited. 10 But little research has been reported on whether Vav3 is related to MDR of gastric cancer. In present study, Vav3 level was examined in both cancer tissue samples and gastric cancer cell lines SGC7901 and the drugresistance cell line SGC7901/adriamycin (ADR). Expressions of MDR genes MDR1/P-glycoprotein (P-gp), lung resistance protein (LRP), glutathione S-transferase-π (GST-π), topoisomerase II α (TopoII α), B cell lymphoma/leukemia-2 (Bcl-2) and Bax were also tested simultaneously. Specific RNA interference technique was further applied to knockdown endogenous Vav3 in drug-resistant cell line SGC7901/ADR to investigate the effect and molecular mechanism of Vav3 on the chemosensitivity of chemotherapy drugs for gastric cancer. It was reported that mitogen-activated protein kinase (MAPK) and PI3K/AKT signal transduction pathway proteins were involved in MDR of gastric cancer by regulating MDR genes. [11] [12] [13] Hence, we also tested the levels total proteins as well as levels of phosphorylated extracellular signal-regulated kinase (ERK), C-Jun, p38 and AKT in SGC7901/ADR cells transfected with Vav3-specific small interfering RNA (Vav3-siRNA), and then the mechanism was explored.
MATERIALS AND METHODS

Clinical samples preparation
A total of 50 cases (30 males and 20 females, aged 37-74 years, with a mean age of 59 years) of gastric adenocarcinoma that had been surgically removed and pathologically confirmed were selected from the Fourth Affiliated Hospital of Hebei Medical University from January to December, 2012. All patients had no underlying diseases such as heart disease, diabetes, hypertension and so on, nor had they received any preoperative chemotherapy or immunotherapy. They were all diagnosed as adenocarcinoma. Gastric mucosal tissues were 5 cm off the edge of cancerous tissues. All tissues were harvested in duplicate, with one stored at − 80°C, while the other fixed in 4% paraformaldehyde and embedded in paraffin as specimen preparation for pathological test.
Cell culture
Human moderately differentiated gastric cancer cell line SGC7901 was purchased from Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Science (Shanghai, China); SGC7901/ADR that was ADR-resistant was a gift from Institute of Gastroenterology, the Fourth Military Medical University. Cells were cultured in DMEM/F12 medium containing 10% fetal calf serum, 100 unit per ml penicillin and 100 mg per ml streptomycin. Cells were incubated in a humidified incubator at 37°C supplemented with 5% CO 2 . SGC7901/ADR cells were cultured in 0.4 mg l − 1 ADR to maintain their resistance phenotype. Trypsin (0.25%) containing 0.02% EDTA was used to trypsinize and split cells. Logarithmic growth phase cells were used in experiments.
Vav3-siRNA transfection Vav3-siRNA sequence was designed and synthesized according to references, 9 which was as follows: siRNA: 5′-CCCAGTTTCTCTGTTTGAAGAACAT-3′. Non-specific control siRNA (NS-siRNA) sequence was as follows: 5′-CCCTT CTCTGTTTGTAAAGAGACAT-3′. Twenty-four hours before transfection, SGC7901/ADR cells were seeded in 6-well plates with the density of 4 × 10 5 ml − 1 . Before transfection, cells were rinsed with serum-free and antibiotics-free DMEM/F12. Using liposome (Invitrogen, Carlsbad, CA, USA)-mediated method, according to the reagents instructions, Vav3-siRNA, diluted with serum-free and antibiotics-free DMEM/F12 medium or by comparing with control NS-siRNA and the corresponding proportion, was transfected with Lipofectamine 2000 (Invitrogen). These two dilutions were mixed to obtain complexes, which were then transfected into SGC7901/ADR cells. Twenty-four hours after transfection, the transfection efficiency as well as expressions of other molecules were detected. Patients were grouped as follows: normally cultured SGC7901/ADR cells (control group), SGC7901/ADR cells transfected with NS-siRNA (NS-siRNA group) and SGC7901/ADR cells transfected with Vav3-siRNA (Vav3-siRNA group).
RNA extraction and real-time quantitative RT-PCR
According to the instructions on Trizol reagent (Invitrogen), the one-step method was used to isolate tissues or total RNAs, to measure RNA purity and concentration. After RNA integrity was confirmed by a 1% agarose gel electrophoresis, 1 μg of total RNAs underwent reverse transcription reaction and real-time PCR reactions according to kit instructions. Twenty microliters of PCR reaction system was established with 1 μl reverse transcription product as a real-time PCR reaction template, 10 μl of 2 × UltraSYBR Mixture, 1 μl of both upstream and downstream primers (10 μmol l − 1 ) and 8 μl DNase-RNase-free water. PCR reaction started with 1 cycle of initial denaturation at 95°C for 5 min, followed by 40 cycles of three steps as denaturation at 95°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 30 s. At the extension phase of each cycle, the fluorescence signals were analyzed. After amplification, GAPDH served as an internal reference, to calculate the relative quantification values (RQ value) of target gene expression, which served as a basis for statistical analysis. The primer sequences were as follows.
Vav3 upstream primer: 5′-TGTGTGCCCAAACCAGTAG-3′, downstream primer: 5′-AAGTTCGGTCTCTGCTTGC-3′; MDR1/P-gp upstream primer: 5′-GT GGGGCAAGTCAGTTCATT-3′; downstream primer: 5′-TCTTCACCTCCAGGCT CAGT-3′; GST-π upstream primer: 5′-GGAGACCTCACCCTGTACCA-3′; downstream primer: 5′-GGCTAGGACCTCATGGATCA-3′; LRP upstream primer: 5′-ACCAACCCTGACGACAGAAG-3′; downstream primer: 5′-CATGTCTCCCGAT CTCTGGT-3′; Topo II α upstream primer: 5′-CAGGTGGTCGTAATGGTTATG-3′; downstream primer: 5′-TTTGGACAGATCTGGTTGGA-3′; Bcl-2 primer: 5′-ACC AACCCTGACGACAGAAG-3′; downstream primer: 5′-CATGTCTCCCGATCTC TGGT-3′; GAPDH primer: 5′-TGAACGGGAAGCTCACTGG-3′; downstream primer: 5′-GCTTCACCACCTTCTTGATGTC-3′.
Western blot analysis
Clinical tissue samples and cells were incubated with an appropriate amount of lysates (1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, pH 8.0, 0.2 mM Na3VO4, 0.2 mM phenylmethylsulfonyl fluoride and 0.5% NP-40). They were split in the ice bath at 4°C for 20 min, and then centrifugated at 8000 r.p.m. for 10 min to collect the supernatant for protein quantification using the BCA method. An equal amount of protein samples were electrically transferred to a PVDF membrane after gel electrophoresis with 10% polyacrylamide. They were added with 5% skim milk powder, closed at room temperature for 2 h, and incubated with diluted Vav3, MDR1/P-gp, LRP, GST-π, Topo II, Bcl-2, AKT, ERK, C-jun N-terminal kinase, p38 and its phosphorylated antibodies or internal reference GAPDH antibody (all from Santa Cruz, Dallas, TX, USA) overnight at 4°C. They were rinsed with TBST for three times and added with the appropriate secondary antibodies for incubation at room temperature for 2 h. They were then rinsed with TBST for three times and with TBS one time; chemiluminescence was used for coloration (Santa Cruz), and bands underwent scanning for integral absorbance. GAPDH served as internal reference. The ratio of absorbance value of each protein to absorbance in the reference value was measured for comparison.
In vitro drug susceptibility testing by sulforhodamine B (SRB) staining Consulting references, 2 at the end of culture phase, 50 μl ice-cold trichloroacetic acid (volume fraction of 50%) was added to each well, to fix cells at 4°C for 1 h. After the fixative was discarded, the wells were rinsed with ultrapure water for five times and dried. Then, 100 μl SRB solution was added to each well for staining in the dark at room temperature for 10 min. SRB solution was then discarded and SRB unbound with protein were rinsed with 1% acetic acid and then naturally dried. Protein-binding SRB was dissolved with 150 μl 10 mmol l − 1 unbuffered Tris alkaline (pH10.5). Absorbance value (OD) at a wavelength of 545 nm was measured by a microplate reader. Growth inhibition rate (%) = (1-experimental group OD value/control group OD value) × 100%.
Statistical analysis
Data are presented as means ± s.e. Statistical analyses were carried out with the SPSS 11.5 statistical software package (SPSS, Chicago, IL, USA). Our primary statistical test was the one-way analysis of variance and Student's t test. Po 0.05 was considered statistically significant.
RESULTS
Expressions of Vav3 and MDR1/P-gp, LRP, GST-π, Topo II α, Bcl-2 as well as Bax Quantitative RT-PCR was applied to detect Vav3 mRNA expression in gastric cancer tissues. The results showed Vav3 mRNA expression was low in the adjacent normal tissues, whereas Vav3 mRNA expression in gastric cancer tissues was significantly higher than that in the adjacent group (P o0.05; Figure 1a ). Western blot analysis was made to detect Vav3 expression, and the result was consistent with that of mRNA, that is, Vav3 protein expression in gastric cancer tissues was significantly higher than that in the adjacent group (P o 0.05; Figure 1b) . The expressions of MDR1/Pgp, LRP, GST-π, Topo II α, Bcl-2 and Bax were very low in adjacent normal tissues, whereas expressions of three kinds of resistance genes MDR1/P-gp, GST-π and Bcl-2 were increased significantly in gastric cancer, compared with those in the adjacent control group (P o 0.05; Figure 1 ).
Detection of cell lines showed that expressions of Vav3 in SGC7901 and SGC7901/ADR were higher than those in gastric epithelial cell line GES-1 (P o 0.05), with even higher Vav3 expression in SGC7901/ADR. In SGC7901 and SGC7901/ADR, expressions of MDR1/P-gp, GST-π and Bcl-2 were significantly elevated compared with those in GES-1, with even higher expression in SGC7901/ADR (P o0.05; Figure 2 ).
Inhibition of activity of SGC7901/ADR at proliferation by knocking down Vav3 expression RNA interference technique was applied to knock down Vav3 expression in SGC7901/ADR cells. Western blot analysis showed that Vav3-siRNA transfection significantly inhibited Vav3 expression of SGC7901/ADR cells, and Vav3 expression showed no significant change in negative control group transfected with NS-siRNA, which indicated that Vav3-siRNA used in this study Vav3 (Figures 3a and b) .
Cell count and SRB test results showed that, compared with NSsiRNA group, the proliferative activity of SGC7901/ADR cells in Vav3-siRNA group was significantly reduced (P o0.05), which suggested that the inhibition of Vav3 expression could inhibit proliferation of SGC7901/ADR cells. When comparing the inhibition of proliferation in NS-siRNA group with that of the control group, there was no significant change (Figures 3c and d) . showed that compared with the NS-siRNA group, the total proteins of signaling pathways above showed no significant change in SGC7901/ADR cells in the Vav3-siRNA group, neither did AKT, ERK and p38 phosphorylation levels. But C-Jun phosphorylation was significantly reduced (P o0.05; Figure 6 ).
DISCUSSION
The Vav3 gene, located on chromosome 1, encodes a protein of 847 amino acids, with a molecular mass of 97.8 kD. The Vav3 protein consists of eight domains. Vav3 is able to regulate multiple signaling pathways through modulating activities of different members of the Rho family. The major downstream signaling pathways affected by Vav3 are PI3K-Akt and NF-κB, 14, 15 which are essential for the development of the body. Animal studies have shown that the Vav3 plays important roles in the normal function of nervous system and cardiovascular system, and the defect of Vav3 expression could lead to abnormality of sympathetic nerve and cardiovascular system. 16, 17 Studies have shown that Vav3 expression is related to various malignancies, such as gastric cancer, 10 skin cancer, 18 prostate cancer, 19 breast cancer, 20 glioblastoma 21 and hepatocellular carcinoma, 22 promoting tumor progression through promotion of tumor cell proliferation, migration and invasion. Our preliminary findings indicate that 23 when Vav3 is overexpressed in gastric cancer cells, the Vav3 gene inhibition can effectively inhibit cell proliferation, migration and invasion, which suggests that Vav3 has a close relationship with gastric cancer. Our results of this study have also showed that when Vav3 expression was increased significantly in gastric cancer cells, it was much higher in the drug-resistant cell line SGC7901/ADR, suggesting that the Vav3 gene might be relevant to MDR in gastric cancer.
Chemotherapy, the chief adjuvant therapy for gastric cancer, plays a key role in the treatment of advanced gastric cancer. However, the curative effect of chemotherapy is affected by many factors, and one of the reasons for the failure of chemotherapy is the drug resistance of tumor cells to chemotherapy. Many genes and signal transduction pathways were invovled in MDR of cancers, and the mechanisms are complicated. [24] [25] [26] [27] The two main mechanisms are as follows: first, the classic resistance mechanism, that is, energy-dependent 'drug pump' mechanism mediated by membrane glycoprotein, and resistance proteins in this category include P-gp, MDR-related protein, LRP and so on; the second category is the resistance mechanism mediated by the enzyme, including resistant proteins Topo, GST-π, thymidylate synthase and protein kinase C. 28 Studies also found that many genes that Vav3 gene and drug resistance of gastric cancer B Tan et al affected tumor cell apoptosis, including Bcl-2 and Bax were also closely associated with MDR of tumors. [29] [30] [31] However, research on Vav3 and drug resistance of gastric cancer has not been reported. Results from our research show that increased Vav3 expression in gastric cancer is correlated with P-gp, GST-π and Bcl-2, indicating that Vav3 may be correlated with the development of gastric cancer drug resistance.
To amplify the role of Vav3 in gastric cancer drug resistance, we used RNA interference technique to inhibit Vav3 in SGC7901/ADR.
We found that the expression of Vav3 siRNA led to increased chemotherapy sensitivity of SGC7901/ADR cells to drugs L-OHP and 5-FU. We also found that Vav3 expression silencing led to lowered expression of drug resistance-related factors MDR1/P-gp, GST-π and Bcl-2, whereas no significant change was found in Bax gene, which suggested that Vav3 was indeed involved in the development of gastric cancer drug resistance, for Vav3 had an effect on expressions of drug resistance-related factors MDR1/P-gp, GST-π and Bcl-2.
Studies have shown that the drug resistance of tumor cells is related to MAPK 27,32-34 and PI3K/Akt 35 signaling pathways. MAPK, a serine/threonine protein kinase and a main signal system in eukaryotic cell, is able to transduct the signal of extracellular stimuli to induce basic physiological response intracellularly. It has been identified that three MAPK signal transduction pathways were present in eukaryotic cells, namely ERK pathway, C-jun N-terminal kinase/stress-activated protein kinase pathway and p38 MAPK pathway. 36 In recent years, the PI3K/Akt signaling pathway is also found to be an important signaling pathway regulating cell growth in eukaryotic cells, with Akt being one of the key elements of this pathway. 37 To clarify which of these signaling pathways is involved in the impact of Vav3 on drug resistance of SGC7901/ ADR cells, we tested these key molecules associated with cell growth signaling pathways after Vav3 was inhibited. The results showed that silencing Vav3 expression could inhibit the activation of C-Jun phosphorylation, without affecting other signaling pathways. Our study confirms that Vav3 is closely associated with the drug resistance of gastric cancer. Inhibition of Vav3 may be realized by inhibiting C-jun N-terminal kinase pathway and the activation of C-Jun proteins phosphorylation, so as to inhibit MDR1/P-gp, GST-π and Bcl-2, for the purpose of reversing the resistant properties of gastric cancer cells. But it is essential to further the study of the molecular mechanisms and applications of Vav3 involved in multidrug resistance of gastric cancer.
